Étiquette : sommeil

Cannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users, Katherine A. Belendiuk et al., 2015

Cannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users Katherine A. Belendiuk, Kimberly A. Babson, Ryan Vandrey, Marcel O. Bonn-Miller Addictive Behaviors, 2015, 50, 178–181 doi : 10.1016/j.addbeh.2015.06.032   a b s t r a c t Introduction : Individuals report using cannabis for the promotion of sleep, and the effects of cannabis on sleep may vary by cannabis species. Little research has documented preferences for particular cannabis types or cannabinoid concentrations as a function of use for sleep disturbances. Methods : 163 adults purchasing medical cannabis for a physical or mental health condition at a cannabis dispensary were recruited. They provided self-report of (a)whether [...]

Lire la suite

Cannabis, Cannabinoids, and Sleep : a Review of the Literature, Kimberly A. Babson et al., 2017

Cannabis, Cannabinoids, and Sleep : a Review of the Literature Kimberly A. Babson, James Sottile, Danielle Morabito Current Psychiatry Reports, 2017, 19, 23 Doi : 10.1007/s11920-017-0775-9   Abstract Purpose of Review : The current review aims to summarize the state of research on cannabis and sleep up to 2014 and to review in detail the literature on cannabis and specific sleep disorders from 2014 to the time of publication. Recent Findings : Preliminary research into cannabis and insomnia suggests that cannabidiol (CBD) may have therapeutic potential for the treatment of insomnia. Delta-9 tetrahydrocannabinol (THC) may decrease sleep latency but could impair sleep quality long-term. Novel studies investigating [...]

Lire la suite

Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review, Jerome Sarris et al., 2020

Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review Jerome Sarris, Justin Sinclair, Diana Karamacoska, Maggie Davidson and Joseph Firth BMC Psychiatry, 2020, 20, 24, 1-14. Doi : 10.1186/s12888-019-2409-8   Abstract Background : Medicinal cannabis has received increased research attention over recent years due to loosening global regulatory changes. Medicinal cannabis has been reported to have potential efficacy in reducing pain, muscle spasticity, chemotherapy-induced nausea and vomiting, and intractable childhood epilepsy. Yet its potential application in the field of psychiatry is lesser known. Methods : The first clinically-focused systematic review on the emerging medical application of cannabis across all major psychiatric disorders was conducted. Current evidence regarding [...]

Lire la suite

Cannabis for Sleep: Short-Term Benefit, Long-Term Disruption ?, Michael Vlessides, 2020

Cannabis for Sleep: Short-Term Benefit, Long-Term Disruption ? Michael Vlessides Medscape, January 24, 2020 https://www.medscape.com/viewarticle/924202_print   Patients suffering from chronic pain who take medicinal cannabis to initiate and maintain sleep appear to experience short-term benefit, but long-term use may ultimately disrupt slumber, new research shows. Investigators found whole-plant medical cannabis use was associated with fewer problems with respect to waking up at night, but they also found that frequent medical cannabis use was associated with more problems initiating and maintaining sleep. "Cannabis may improve overall sleep in the short term," study investigator Sharon Sznitman, PhD, University of Haifa Faculty of Social Welfare and Health Sciences in Israel, [...]

Lire la suite

Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients : a prospective cohort study, Alex Capano et al., 2019

Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients : a prospective cohort study Alex Capano, Richard Weaver & Elisa Burkman Postgraduate Medicine, 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. Doi : 10.1080/00325481.2019.1685298   ABSTRACT Context : Chronic pain is highly prevalent in most of the industrialized nations around the world. Despite the documented adverse effects, opioids are widely used for pain management. Cannabinoids, and specifically Cannabidiol, is proposed as an opioid alternative, having comparable efficacy with better safety profile. Objectives : We aim to investigate the impact [...]

Lire la suite

Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms : An Observational Study of 18 Participants Undergoing Compassionate Use, Paulo Fleury-Teixeira et al., 2019

Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms : An Observational Study of 18 Participants Undergoing Compassionate Use Paulo Fleury-Teixeira, Fabio Viegas Caixeta, Leandro Cruz Ramires da Silva, Joaquim Pereira Brasil-Neto and Renato Malcher-Lopes Frontiers in Neurology, October 2019, Volume 10, Article 1145 doi : 10.3389/fneur.2019.01145   Autism Spectrum Disorders comprise conditions that may affect cognitive development, motor skills, social interaction, communication, and behavior. This set of functional deficits often results in lack of independence for the diagnosed individuals, and severe distress for patients, families, and caregivers. There is a mounting body of evidence indicating the effectiveness of pure cannabidiol (CBD) and [...]

Lire la suite

Using Cannabis To Help You Sleep: Heightened Frequency of Medical Cannabis Use among Those with PTSD, Marcel O. Bonn-Miller et al., 2014,

Using Cannabis To Help You Sleep: Heightened Frequency of Medical Cannabis Use among Those with PTSD Marcel O. Bonn-Miller, Kimberly A. Babson, and Ryan Vandrey Drug and Alcohol Dependence, 2014, 136, 162–165. doi:10.1016/j.drugalcdep.2013.12.008   Abstract Background : The use of cannabis for medical purposes is proliferating in the U.S., and PTSD is an explicitly approved condition for accessing medical cannabis in 5 states. Prior research suggests that people with PTSD often use cannabis to help cope with their condition, and that doing so results in more frequent and problematic cannabis use patterns. Specific coping motivations, such as sleep improvement, among medical cannabis users, have not been [...]

Lire la suite

Cannabis For Cancer-Related Symptoms (CAFCARS), ClinicalTrials.gov Identifier : NCT03948074, mai 2019

Cannabis For Cancer-Related Symptoms (CAFCARS) https://clinicaltrials.gov/ct2/show/NCT03948074?recrs=abdf&cond=cannabis&draw=2&rank=98 ClinicalTrials.gov Identifier: NCT03948074 Recruitment Status : Not yet recruiting First Posted : May 13, 2019 Last Update Posted : May 13, 2019 See Contacts and Locations Sponsor: Pippa Hawley Information provided by (Responsible Party): Pippa Hawley, British Columbia Cancer Agency Study Description Brief Summary: Clinical evidence is urgently needed to be able to advise patients on which cannabis-based products to take, or to avoid, in managing cancer-related symptoms. This trial was therefore designed to determine which cannabis extract combination (High THC-Low CBD, Low THC-High CBD, or Equal amounts of THC and CBD) is most effective at treating cancer related symptoms for each [...]

Lire la suite

Cannabidiol in Anxiety and Sleep : A Large Case Series, Scott Shannon et al., 2019

Cannabidiol in Anxiety and Sleep : A Large Case Series Scott Shannon, Nicole Lewis, Heather Lee,  Shannon Hughes, The Permanente Journal, 2019, 23, 18-041 doi.org/10.7812/TPP/18-041   ABSTRACT Context : Cannabidiol (CBD) is one of many cannabinoid compounds found in cannabis. It does not appear to alter consciousness or trigger a “high.” A recent surge in scientific publications has found preclinical and clinical evidence documenting value for CBD in some neuropsychiatric disorders, including epilepsy, anxiety, and schizophrenia. Evidence points toward a calming effect for CBD in the central nervous system. Interest in CBD as a treatment of a wide range of disorders has exploded, yet few clinical [...]

Lire la suite

3,4-Methylenedioxymethamphetamine assisted psychotherapy for treatment of chronic posttraumatic stress disorder : A randomized phase 2 controlled trial, Marcela Ot’alora G et al., 2018

3,4-Methylenedioxymethamphetamine assisted psychotherapy for treatment of chronic posttraumatic stress disorder : A randomized phase 2 controlled trial Marcela Ot’alora G, Jim Grigsby, Bruce Poulter1, Joseph W Van Derveer III, Sara Gael Giron, Lisa Jerome, Allison A Feduccia, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, Michael C Mithoefer and Rick Doblin Journal of Psychopharmacology, 2018, 1-13 Doi : 10.1177/0269881118806297   Abstract Background : Posttraumatic stress disorder often does not resolve after conventional psychotherapies or pharmacotherapies. Pilot studies have reported that 3,4-methylenedioxymethamphetamine (MDMA) combined with psychotherapy reduces posttraumatic stress disorder symptoms. Aims : This pilot dose response trial assessed efficacy and safety of MDMA-assisted psychotherapy across multiple therapy teams. Methods : [...]

Lire la suite